As of 10:33:04 AM GMT. Market Open.
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ISK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Riad Sherif M.B.A., M.D. | CEO & Director | -- | -- | 1968 |
| Ms. Sylvia Cheung | Chief Financial Officer | -- | -- | 1975 |
| Ms. Gudrun Bachmann Ph.D. | Chief Technology Officer | -- | -- | -- |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. Daniel S. Char J.D. | Chief Legal Officer | -- | -- | 1961 |
| Ms. Virginia R. Dean | Chief Human Resources Officer | -- | -- | 1967 |
| Mr. Páll Ragnar Jóhannesson | Chief Business Officer | -- | -- | 1982 |
| Ms. Rebecca Weil | Chief Commercial Officer | -- | -- | -- |
| Dr. Snehal Shah Pharm.D. | President of Research & Development | -- | -- | -- |
| Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer | -- | -- | -- |
Oculis Holding AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 36
Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Corporate Governance
Oculis Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 7, 2024 at 9:00 AM UTC
Oculis Holding AG Earnings Date
Recent Events
Recent Events Information Not Available